Physician profile
Abigail Soto
NPI 1538592506
$1,270.57
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.22 · 2020: $200 · 2021: $614 · 2022: $144 · 2023: $230 · 2024: $52.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $451.14 | 2021-2023 | Linzess, Creon |
| Lilly USA, LLC | $204.40 | 2020-2024 | Trulicity, Mounjaro, Jardiance |
| Novo Nordisk INC | $152.97 | 2019-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $79.22 | 2020-2022 | |
| Amgen INC. | $65.41 | 2021-2023 | Otezla, Repatha |
| Biosense Webster, INC. | $55.18 | 2021 | |
| Allergan, INC. | $54.91 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.78 | 2020-2024 | Xifaxan |
| Pfizer INC. | $40.97 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.94 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $19.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.62 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.54 | 2021 | |
| Seqirus USA INC | $18.04 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Idorsia Pharmaceuticals US INC | $13.03 | 2023 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Soto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.